tiprankstipranks
Chemring Group PLC (GB:BC88)
LSE:BC88
UK Market

Chemring (BC88) Earnings Dates, Call Summary & Reports

4 Followers

Earnings Data

Report Date
Jun 09, 2026
Before Open (Not Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
Last Year’s EPS
Same Quarter Last Year
Based on 0 Analysts Ratings

Earnings Call Summary

Q4 2025
Earnings Call Date:Dec 09, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The call presented a largely positive operational and financial picture: record order intake and order book, modest revenue growth, expanding margins, exceptional cash conversion and strong Energetics and countermeasures performance underpin medium-term growth. Notable near-term challenges include Roke's decline driven by UK budget timing, a material CapEx increase in Norway (partially grant-funded), higher near-term capital spend and lower cash conversion guidance for FY '26, and some underperforming legacy assets being divested. On balance, the strategic wins, strong balance sheet, and execution evidence outweigh the short-term timing and cost pressures.
Company Guidance
Guidance was unchanged for FY26 with c.76% of revenue already covered and a similar H2 weighting to FY25; group targets include Countermeasures & Energetics growth of low double-digits (Energetics mid‑teens, Countermeasures low single‑digits) and Sensors & Information mid‑double‑digit growth, with U.S. Sensors flat as JBTDS waits FRP (expected FY27) and Roke returning to near FY24 revenue with H2‑weighted recovery and a target of GBP250m by FY28; order cover remains strong (95% for ’26, 93% for ’27, 59% for ’28), CapEx for FY26 is guided at GBP100–110m (higher due to Norway), interest costs about GBP10m, cash conversion expected 80–85% in FY26 (returning to normal in the medium term), leverage target remains <1.5x, dividend cover target of 2.5x is being maintained, GBP36m remains on the buyback, and the long‑term ambition is to double revenue to GBP1bn by 2030 while maintaining strong margins.
Record Order Intake and Order Book
Order intake reached GBP 781 million, up 20% year-on-year, delivering a record order book of GBP 1.3 billion (up 32% YoY), providing strong visibility into future revenue.
Revenue and Margin Improvement
Group revenue increased by 2% to GBP 498 million (3% at constant currency), operating profit rose 6%, and operating margin improved by 50 basis points to 14.8%, reflecting operational effectiveness.
Strong Cash Generation and Balance Sheet
Cash conversion rose to 114% with operating cash of GBP 112 million. Closing net debt was GBP 89 million (~0.9x leverage), supporting continued investment and disciplined capital returns (buyback and dividend).
Energetics & Countermeasures Outperformance
Countermeasures & Energetics revenue grew 17%. Energetics delivered ahead of schedule with operational improvements: operating profit in countermeasures grew 37% and margin widened to 19.1% (up 280 basis points). Expansion projects (Chicago, Scotland, Norway) largely complete or advancing and expected to add ~GBP 100 million revenue and GBP 30 million operating profit p.a. from 2028.
Strategic Contract Wins
Secured several strategically important contracts including STORM (Roke's GBP 251 million UK MOD multiyear missile defense program) and GBP 65 million of Roke national security contract renewals, strengthening future revenue pipeline.
Safety and ESG Progress
Total recordable injury frequency rate (TRIFR) improved from 0.69 to 0.48, demonstrating progress on the group's safety agenda and 'zero harm' ambition.
Product & Technology Momentum
New product launches and wins (CORTEXA counter-drone system; DECEIVE EW system) with early pre-production sales and international interest; U.S. sensors secured a USD 15 million naval biologic detector order; Landguard acquisition completed and integrated as planned.
Shareholder Returns
Final dividend declared of 5.3p, total dividend 8p (up 3%), continued buyback activity with GBP 36 million remaining authority.

Chemring (GB:BC88) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

GB:BC88 Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Jun 09, 2026
2026 (Q2)
- / -
Dec 09, 2025
2025 (Q4)
- / -
Jun 03, 2025
2025 (Q2)
- / -
Dec 17, 2024
2024 (Q4)
- / -
Jun 04, 2024
2024 (Q2)
- / -
Dec 12, 2023
2023 (Q4)
- / -
Jun 06, 2023
2023 (Q2)
- / -
Dec 13, 2022
2022 (Q4)
- / -
Jun 08, 2022
2022 (Q2)
- / -
Dec 14, 2021
2021 (Q4)
- / -
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

GB:BC88 Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Dec 09, 2025
97.00 p97.00 p0.00%
Jun 03, 2025
97.00 p97.00 p0.00%
Dec 17, 2024
97.00 p97.00 p0.00%
Jun 04, 2024
97.00 p97.00 p0.00%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Chemring Group PLC (GB:BC88) report earnings?
Chemring Group PLC (GB:BC88) is schdueled to report earning on Jun 09, 2026, Before Open (Not Confirmed).
    What is Chemring Group PLC (GB:BC88) earnings time?
    Chemring Group PLC (GB:BC88) earnings time is at Jun 09, 2026, Before Open (Not Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is the P/E ratio of Chemring Group PLC stock?
          The P/E ratio of Chemring is N/A.
            What is GB:BC88 EPS forecast?
            Currently, no data Available